Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
1,139,909
1,247,259
1,372,706
1,311,665
1,300,316
1,306,348
Cost of Goods Sold (COGS) incl. D&A
366,628
371,861
377,983
356,340
330,088
327,262
Gross Income
773,281
875,398
994,723
955,325
970,228
979,086
SG&A Expense
588,478
659,115
725,085
678,906
698,987
698,945
EBIT
184,803
216,283
269,638
-
271,241
280,141
Unusual Expense
67,070
60,425
22,734
32,109
44,123
44,018
Non Operating Income/Expense
2,588
33,272
16,381
39,681
6,927
13,084
Interest Expense
458
468
1,257
1,334
1,309
1,302
Pretax Income
120,524
189,466
263,013
281,769
218,113
248,967
Income Tax
31,101
53,827
68,083
63,069
53,434
26,702
Equity in Affiliates
1,451
217
1,243
-
-
-
Consolidated Net Income
90,874
135,856
193,687
218,701
164,679
222,265
Net Income
90,874
135,856
193,687
218,701
164,679
222,265
Net Income After Extraordinaries
90,874
135,856
193,687
218,701
164,679
222,265
Net Income Available to Common
90,874
135,856
193,687
218,701
164,679
222,265
EPS (Basic)
40.45
61.50
89.75
103.69
81.11
115.05
Basic Shares Outstanding
2,247
2,209
2,158
2,109
2,030
1,932
EPS (Diluted)
40.39
61.40
89.62
103.55
81.02
114.94
Diluted Shares Outstanding
2,250
2,212
2,161
2,112
2,032
1,934
EBITDA
249,107
281,757
338,826
340,210
336,104
343,599
Non-Operating Interest Income
661
804
985
978
1,648
2,690
Equity in Affiliates (Pretax)
-
-
-
1,864
2,419
1,627

About Astellas Pharma

View Profile
Address
2-5-1 Nihonbashi-Honcho
Tokyo Tokyo 103
Japan
Employees -
Website http://www.astellas.com
Updated 07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.